Find News

Filter articles

Applied Filters

Showing 51 to 60 of 130 results

Samsung makes move into novel drugs market

Japan, South Korea22-08-2017

Samsung’s biopharmaceutical arm Samsung Bioepis has agreed a deal with Takeda to tackle “unmet disease areas”, marking the South Korean company’s move into the novel drugs market.

China launches life sciences IP centre


China has launched an IP rights protection centre aimed at providing protection for the biopharmaceutical and high-end manufacturing industries. 

Takeda enters $100m licensing agreement with Tesaro

Japan, Russia, South Korea, Taiwan01-08-2017

Takeda has entered into an exclusive licensing agreement with biopharmaceutical company Tesaro to develop a novel cancer therapy in Japan.

Mitsubishi Tanabe to buy NeuroDerm for $1.1bn

Israel, Japan25-07-2017

Mitsubishi Tanabe has agreed to acquire NeuroDerm, a clinical stage pharmaceutical company, for $1.1 billion.

BIO 2017: The success story of OmniRat


The creator of OmniRat, the first human monoclonal antibody technology based on rats, outlined the success story of the project yesterday at the 2017 BIO International Convention.

Merck granted its first CRISPR patent in Australia


Merck has been granted its first CRISPR technology patent by the Australian Patent Office.

WIPO reveals new plan to fight tropical diseases


The World Intellectual Property Organization’s Re:Search has launched a new five-year guide to its activities in the fight against neglected tropical diseases, malaria and tuberculosis.

WHO to make biosimilars more available in poor countries


The World Health Organization will launch a pilot project for biosimilars to make costly cancer treatments more widely available in low and middle income countries.

Hepatitis C drugs face four patent challenges in India

Argentina, India15-02-2017

India-based Initiative for Medicines, Access & Knowledge has filed four patent challenges against patents covering hepatitis C drugs in a bid to ensure access to affordable treatment.

IP strategy chief focus for life sciences counsel, says report


Global intellectual property strategy will be the chief area of focus for IP counsel in the life sciences arena in 2017.

Showing 51 to 60 of 130 results